• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Bris­tol My­ers re­serves a cen­ter spot at Alexan­dri­a's big San Diego biotech R&D hub

4 years ago
Pharma

FDA hands Bris­tol My­ers a land­mark ap­proval in ear­ly-stage lung can­cer af­ter just five days

4 years ago
FDA+

Pas­cal So­ri­ot bud­gets a fi­nal £100M to fin­ish As­traZeneca's new HQ — now 9 years and £1B-plus in the mak­ing

4 years ago
Pharma

In pas­sion­ate ap­peal, Enam­ine CEO asks for phar­ma in­dus­try's help to iso­late Rus­sia and slow in­va­sion

4 years ago
Pharma

Blue­bird CFO re­signs as com­pa­ny faces bleak eco­nom­ic fu­ture

4 years ago
People
Pharma

The Pfiz­er pa­pers; Bio­gen lay­offs be­gin; Ab­b­Vie inks a buy­out; GSK makes Slaoui pay; and more

4 years ago
Weekly

Health Cana­da is­sues two re­calls for Pfiz­er blood pres­sure drugs over im­pu­ri­ty

4 years ago
Pharma

Type 2 di­a­betes drugs and weight loss: Cal­i­brate's mod­el starts with phar­ma and builds out

4 years ago
Pharma
Marketing

Sanofi pe­ti­tions FDA over 'mis­lead­ing' la­bel for ri­val flu vac­cine that failed to con­firm ben­e­fit

4 years ago
R&D
Pharma

'Re­call ready': FDA urges com­pa­nies to com­ply with drug re­call guid­ance

4 years ago
Manufacturing

In new re­search pa­per, No­var­tis out­lines how an old SMA pro­gram could al­ter the course of Hunt­ing­ton's

4 years ago
Discovery

Eli Lil­ly launch­es new Verzenio mes­sag­ing aimed at ear­ly-stage breast can­cer pa­tients

4 years ago
Pharma
Marketing

For­mer Warp Speed chief agrees to pay GSK back $3.9M fol­low­ing sex­u­al ha­rass­ment

4 years ago
People
Coronavirus

BeiGene's hema­tol­ogy CMO is on her way out amid mar­ket tur­moil

4 years ago
People

With all eyes on Chi­nese-on­ly on­col­o­gy da­ta, Co­herus and Jun­shi un­cork win for PD-1 drug in esophageal can­cer

4 years ago
R&D
China

Ex­clu­sive: GV’s first net­work de­vel­op­ment part­ner com­pletes ‘full cir­cle’; Just when En­zy­vant scores an ...

4 years ago
Peer Review

UK to in­vest $345M to bol­ster life sci­ence re­search, man­u­fac­tur­ing ca­pa­bil­i­ties

4 years ago
Financing

In Ger­man-on­ly an­nounce­ment, Bay­er in­vests $1.5B in­to na­tive coun­try man­u­fac­tur­ing

4 years ago
Manufacturing

Covid-19 roundup: Sh­iono­gi vac­cine proves ef­fec­tive — re­port; Eli Lil­ly, In­cyte's JAK re­duces death, study finds

4 years ago
Coronavirus

Small biotech CEO ex­o­dus con­tin­ues as vTv, a trou­bled for­mer Alzheimer's play­er, sees chief leave af­ter just 4 months

4 years ago
People

Sack­ler fam­i­ly reach­es new $6B agree­ment with states over opi­oid cri­sis

4 years ago
Pharma
Marketing

NIH of­fers to share Covid-19 tech­nolo­gies with WHO — re­port

4 years ago
Pharma
Coronavirus

Non­prof­it Civi­ca goes af­ter in­sulin prices in a big way, prep­ping for $30 vials by 2024

4 years ago
Pharma

Au­rinia faces chop­py wa­ters amid low­er-than-ex­pect­ed 2022 guid­ance and patent chal­lenge on Lup­ky­nis

4 years ago
Pharma
FDA+
First page Previous page 572573574575576577578 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times